Lutris Pharma Revenue and Competitors
Employee Data
- Lutris Pharma has 4 Employees.
- Lutris Pharma grew their employee count by 0% last year.
Lutris Pharma's People
Name | Title | Email/Phone |
---|
Lutris Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 23 | 53% | N/A | N/A |
#2 | N/A | 49 | 40% | N/A | N/A |
#3 | N/A | 32 | 7% | N/A | N/A |
#4 | N/A | 15 | -6% | N/A | N/A |
#5 | N/A | 43 | 26% | N/A | N/A |
#6 | N/A | 28 | 0% | N/A | N/A |
#7 | N/A | 24 | 9% | N/A | N/A |
#8 | N/A | 8 | 0% | N/A | N/A |
#9 | N/A | 19 | 6% | N/A | N/A |
#10 | N/A | 4 | 0% | N/A | N/A |
What Is Lutris Pharma?
Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.
keywords:N/AN/A
Total Funding
4
Number of Employees
N/A
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.5M | 4 | -20% | N/A |
#2 | $0.3M | 4 | N/A | N/A |
#3 | $0.5M | 4 | -20% | N/A |
#4 | $0.6M | 4 | -50% | N/A |
#5 | $0.4M | 4 | -20% | N/A |